NasdaqGM:HROWPharmaceuticals
Does Harrow’s Recent FDA News Signal an Opportunity After a 7.5% Decline?
Considering adding Harrow to your portfolio and curious whether its current price is a bargain? You are not alone. Let's get to the bottom of whether it's undervalued or if there's more beneath the surface.
The stock has shown some interesting moves lately, with returns of -3.4% over the past week, a modest 1.0% uptick for the last month, a solid 6.4% gain year-to-date, though it is still down -7.5% for the last year.
Many investors have been watching Harrow closely after...